引用本文:任汉云.异基因造血干细胞移植治疗恶性血液病的现状及展望[J].中国临床新医学,2023,16(11):1105-1109.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 365次   下载 588 本文二维码信息
码上扫一扫!
分享到: 微信 更多
异基因造血干细胞移植治疗恶性血液病的现状及展望
任汉云
100034 北京,北京大学第一医院血液科
摘要:
[摘要] 异基因造血干细胞移植(allo-HSCT)是根治恶性血液病的有效手段,在全球范围内广泛应用。近20年allo-HSCT蓬勃发展,移植数量逐年增加,移植方案不断优化,移植疗效和安全性不断提高。该文介绍allo-HSCT治疗恶性血液病的现状并对未来可能的发展方向进行展望。
关键词:  异基因造血干细胞移植  恶性血液病  预处理  移植物抗宿主病
DOI:10.3969/j.issn.1674-3806.2023.11.01
分类号:R 55
基金项目:
Current status and outlook of allogeneic hematopoietic stem cell transplantation for malignant hematologic diseases
REN Han-yun
Department of Hematology, Peking University First Hospital, Beijing 100034, China
Abstract:
[Abstract] Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is an effective mean for eradicating malignant hematologic diseases and is widely used around the world. In the past 20 years, allo-HSCT has flourished with the increased number of transplants year by year and the continuous optimization of transplantation protocols, and the clinical efficacy and safety of the transplantation have been continuously improved. In this paper, the current status of allo-HSCT in the treatment of malignant hematologic diseases is introduced and an outlook on possible future research directions is raised.
Key words:  Allogeneic hematopoietic stem cell transplantation(allo-HSCT)  Malignant hematologic disease  Conditioning  Graft-versus-host disease